胸腺肽α_1联合顺铂灌注治疗恶性胸腔积液的临床观察  

Clinical Observation of Cisplatin Combined with Thymosin α_1 for Malignant Pleural Effusion with Intrapleural Infusion

作　　者：霍伟[1] 朱晓敏[1] 潘鑫焱[1] 高羽[1] 李志民[1] 

机构地区：[1]大连市中心医院肿瘤内科,辽宁大连116033

出　　处：《中国药房》2014年第20期1867-1869,共3页China Pharmacy

摘　　要：目的:观察胸腺肽α1联合顺铂治疗恶性胸腔积液的疗效和安全性。方法:将96例恶性胸腔积液患者随机均分为治疗组和对照组。两组患者均于胸腔中心静脉导管置管引流排尽胸腔积液后胸腔内灌注药物,治疗组患者灌注顺铂与胸腺肽α1及地塞米松;对照组患者灌注顺铂及地塞米松。两组患者均每周1次,共治疗4次。比较两组患者的治疗效果、患者的生存质量及免疫功能指标,观察两组不良反应发生情况。结果:治疗后治疗组患者的总有效率(85.4%)显著高于对照组(60.4%),且治疗组患者的Karnofsky评分改善率(72.9%)显著高于对照组(50.0%),两组比较差异均有统计学意义(P<0.05)。治疗后治疗组患者的CD4、CD4/CD8、自然杀伤淋巴细胞显著高于对照组(P<0.05)。两组患者的不良反应发生率比较,差异无统计学意义(P>0.05)。结论:胸腔中心静脉导管置管引流后灌注顺铂与胸腺肽α1治疗恶性胸腔积液疗效较好,可以改善患者的生存质量及免疫功能,且安全性较好。OBJECTIVE： To observe clinical efficacy and ADR of thymosin α1 combined with cisplatin for malignant pleural ef fusion, METHODS： 96 patients with malignant pleural effusion were randomly divided into therapey group and control group. Both groups were given intrapleural infusion of relevant drugs after drained pleural effusion by central venous catheter installation. Thera py group was given cisplatin, thymosin ctl and dexamethasone; control group was given cisplatin and dexamethasone. Both of groups were treated 1 times each week for 4 times. Therapeutic efficacy, quality of life and immunologic function index and ADR rate were compared between 2 groups. RESULTS： The total effective rate of therapy group （85.4%） was significantly higher than that of control group （60.4%） ; Karnofsky score of therapy group （72.9%） was significantly higher than that of control group （50.0%） ; there were statistical significances （P〈0.05）. After treatment, the levels of CD4 and CD4/CD8 and NK cell activity in therapy group were significantly higher than in control group （P〈0.05）. The incidence of ADR had no statistical significance be tween 2 groups （P〉0.05）. CONCLUSIONS： The intrapleural infusion of cisplatin and thymosin α1 is effective for malignant pleu ral effusion after drainage by central venous catheter installation, can improve the quality of life and immunologic function and have no effect on the occurrence of ADR.

关 键 词：顺铂 胸腺肽Α1 恶性胸腔积液 疗效 生存质量 

分 类 号：R561[医药卫生—呼吸系统]